ReviewCurrent atherosclerosis reports2026
To Reenvision and Redefine: Considering the Role of Lifestyle Interventions in the New Era of Second-Generation Obesity Management Medications.
Review in Current atherosclerosis reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purpose of reviewThis narrative review examines lifestyle considerations before, during, and after second-generation obesity management medication (OMM) treatment. RECENT
findingsSecond-generation OMMs, including semaglutide and tirzepatide, have demonstrated unprecedented weight losses of around 15-20% in recent trials, leading to their swift uptake in clinical care. With increased pharmacotherapy effectiveness, attention has shifted to the accompanying role of lifestyle interventions in optimizing health and wellbeing. Emerging literature raises concerns regarding treatment sustainability, lean mass loss, nutritional risks, and weight regain following pharmacotherapy discontinuation, highlighting persistent gaps in the role of lifestyle strategies during OMM treatment. Lifestyle modification remains the cornerstone of obesity treatment, yet barriers to implementation and long-term success underscore the need for more sustainable strategies. As novel OMMs redefine obesity care, lifestyle programs may be able to shift focus from weight reduction to overall health promotion. However, the optimal timing, frequency, and content of such interventions alongside OMMs remain unclear. Because obesity is chronic and OMMs are costly, pre-treatment programs may precede pharmacotherapy, though this can limit access and reinforce stigma. During treatment, lifestyle approaches can mitigate medication-related effects and enhance health beyond weight loss, addressing concerns such as inadequate nutrition or muscle loss through protein intake and physical activity and reducing gastrointestinal side effects via dietary strategies. After discontinuation, behavioral programs may help prevent weight regain and sustain health improvements. Tailoring lifestyle interventions to modern pharmacotherapy offers an opportunity for health-centered, patient-focused obesity care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.